Edition:
United Kingdom

Zynerba Pharmaceuticals Inc (ZYNE.OQ)

ZYNE.OQ on NASDAQ Stock Exchange Global Market

11.47USD
15 Dec 2017
Change (% chg)

$0.05 (+0.44%)
Prev Close
$11.42
Open
$11.45
Day's High
$11.92
Day's Low
$11.41
Volume
105,373
Avg. Vol
195,281
52-wk High
$25.95
52-wk Low
$5.42

Latest Key Developments (Source: Significant Developments)

Zynerba Pharmaceuticals reports Q3 loss per share of $0.63
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Zynerba Pharmaceuticals Inc :Zynerba Pharmaceuticals reports third quarter 2017 financial results and operational highlights.Q3 loss per share $0.63.Q3 earnings per share view $-0.59 -- Thomson Reuters I/B/E/S.Zynerba Pharmaceuticals - ‍ believes cash and cash equivalent position as of September 30, 2017 is sufficient to develop five phase 3-ready programs.Zynerba Pharmaceuticals Inc - believes that cash and cash equivalent position of as of September 30, 2017 is sufficient to fund operations into 2019​.  Full Article

Zynerba enters into an open market sale agreement with Jefferies
Thursday, 1 Sep 2016 

Zynerba Pharmaceuticals Inc : Entered into an open market sale agreement with Jefferies Llc, or Jefferies, as placement agent - SEC filing .Pursuant to agreement co may issue, sell shares of common stock in an aggregate offering price of up to $30.0 million.  Full Article

Zynerba Pharmaceuticals files for mixed shelf of up to $150 mln
Thursday, 1 Sep 2016 

Zynerba Pharmaceuticals Inc :Zynerba Pharmaceuticals Inc files for mixed shelf of up to $150 million -SEC filing.  Full Article

Zynerba Pharmaceuticals reported Q2 EPS ($0.70)
Thursday, 11 Aug 2016 

Zynerba Pharmaceuticals Inc : Q2 loss per share $0.70 . Zynerba Pharmaceuticals reports second quarter 2016 financial results and organizational changes . Q2 earnings per share view $-0.54 -- Thomson Reuters I/B/E/S . Expects its existing cash and cash equivalents will fund its research and development programs and operations through 2017 .Jim Fickenscher will replace Richard Baron as Chief Financial Officer.  Full Article

Zynerba Pharma Q1 loss per share $0.49
Thursday, 12 May 2016 

Zynerba Pharmaceuticals Inc : Expects that existing cash and cash equivalents will fund its research and development programs and operations through 2017 . Zynerba pharmaceuticals reports first quarter 2016 financial results and operational highlights . Q1 loss per share $0.49 .Q1 earnings per share view $-0.56 -- Thomson Reuters I/B/E/S.  Full Article

Zynerba Pharmaceuticals Inc announces positive initial results from ZYN002 CBD Gel Phase 1 Single Rising Dose Trial
Wednesday, 6 Jan 2016 

Zynerba Pharmaceuticals Inc:Announced positive initial safety results from its Phase 1 single rising dose clinical trial of its ZYN002 cannabidiol (CBD) gel in development for the treatment of epilepsy, osteoarthritis and Fragile X Syndrome.Final results, including results from patients with epilepsy, are expected in the first half of 2016.  Full Article

Therapix expects to have results of Tourette's drug trial by end of Q1

TEL AVIV, Dec 4 Israel's Therapix Biosciences said on Monday it expects by the end of March to have the results from its mid-stage trial of a cannabinoid-based drug for treating Tourette's syndrome which could be worth billions of dollars in revenues.